(CMRX) Chimerix - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US16934W1062

CMRX: Cancer, Brain Tumor, Neuroendocrine Tumor, Antiviral

Chimerix, Inc. (NASDAQ:CMRX) is a biopharmaceutical company focused on developing innovative antiviral and oncology therapies. Its lead candidate, ONC201, is in Phase 3 trials for H3 K27M-mutant diffuse glioma and Phase 2 for rare neuroendocrine tumors. ONC206, a first-in-class DRD2 antagonist and ClpP agonist, is in Phase 1 for primary CNS tumors. The pipeline also includes ONC212, targeting GPR132, and CMX521, a nucleoside analog for SARS-CoV-2. Chimerix has a license agreement with SymBio Pharmaceuticals for TEMBEXA, excluding smallpox applications. Incorporated in 2000, the company is based in Durham, North Carolina.

Chimerixs pipeline emphasizes first-in-class therapeutics, addressing unmet needs in oncology and antiviral treatments. Their approach combines a deep understanding of tumor biology with innovative drug development, focusing on rare and deadly diseases. The companys strategic partnerships, like with SymBio, enhance its commercialization capabilities, particularly for TEMBEXA.

Ticker Symbol: CMRX Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology Average Volume 20d: 1,853,918 Last Price: 4.74 SMA 20: 4.44 SMA 50: 3.84 SMA 200: 1.67 ATR: 0.32 Market Cap: 420.18M USD P/E: 0.00 P/E Forward: 1.21 P/B: 3.16 P/S: 2,642.62 RoE: -61.57

3-Month Forecast: Based on and , CMRX is expected to experience volatility. The stock price may fluctuate between $4.00 and $5.50, influenced by clinical trial progress and partnership developments. The relatively low trading volume could amplify price movements. On the upside, positive Phase 3 results for ONC201 or ONC206 advancements could drive gains. Conversely, delays or negative data may lead to a pullback. The forward P/E of 1.21 suggests potential undervaluation, but the negative RoE indicates ongoing losses. The next quarter will likely see increased investor focus on clinical milestones and partnership expansions.

Additional Sources for CMRX Stock

CMRX Stock Overview

Market Cap in USD 758m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2013-04-11

CMRX Stock Ratings

Growth 5y 23.3%
Fundamental -
Dividend 0.0%
Rel. Strength Industry 703
Analysts 4.8/5
Fair Price Momentum 7.55 USD
Fair Price DCF -

CMRX Dividends

No Dividends Paid

CMRX Growth Ratios

Growth Correlation 3m 97.4%
Growth Correlation 12m 40.1%
Growth Correlation 5y -66.3%
CAGR 5y 43.02%
CAGR/Max DD 5y 0.46
Sharpe Ratio 12m -0.02
Alpha 646.46
Beta -1.32
Volatility 67.19%
Current Volume 2242k
Average Volume 20d 2138.2k
What is the price of CMRX stocks?
As of March 16, 2025, the stock is trading at USD 8.46 with a total of 2,241,975 shares traded.
Over the past week, the price has changed by +0.36%, over one month by +93.15%, over three months by +190.72% and over the past year by +642.11%.
Is Chimerix a good stock to buy?
Neither. Based on ValueRay Analyses, Chimerix is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 23.26 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CMRX as of March 2025 is 7.55. This means that CMRX is currently overvalued and has a potential downside of -10.76%.
Is CMRX a buy, sell or hold?
Chimerix has received a consensus analysts rating of 4.80. Therefor, it is recommend to buy CMRX.
  • Strong Buy: 4
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CMRX stock price target?
According to ValueRays Forecast Model, CMRX Chimerix will be worth about 8.2 in March 2026. The stock is currently trading at 8.46. This means that the stock has a potential downside of -3.66%.
Issuer Forecast Upside
Wallstreet Target Price 8.5 0.9%
Analysts Target Price 8.4 -0.7%
ValueRay Target Price 8.2 -3.7%